0001657312 false X0 GB 0001657312 2023-09-11 2023-09-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): September 11, 2023

 

 

 

Verona Pharma plc

(Exact name of registrant as specified in its charter)

 

 

 

United Kingdom   001-38067   98-1489389

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

3 More London Riverside

London SE1 2RE

United Kingdom

(Address of principal executive offices) (Zip Code)

 

+44 203 283 4200

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Ordinary shares, nominal value £0.05 per share* VRNA The Nasdaq Stock Market LLC
(Nasdaq Global Market)

 

* The ordinary shares are represented by American Depositary Shares (each representing 8 ordinary shares), which are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 8.01 Other Events.

 

On September 11, 2023, Verona Pharma plc (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the Company’s New Drug Application (“NDA”) for ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease. The FDA has assigned a Prescription Drug User Fee Act target action date of June 26, 2024 and is not currently planning to hold an advisory committee meeting to discuss the NDA.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    VERONA PHARMA PLC
     
Date: September 11, 2023   By: /s/ David Zaccardelli 
    Name: David Zaccardelli, Pharm.D.
    Title: President and Chief Executive Officer

 

 

 

 

 

v3.23.2
Cover
Sep. 11, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 11, 2023
Entity File Number 001-38067
Entity Registrant Name Verona Pharma plc
Entity Central Index Key 0001657312
Entity Tax Identification Number 98-1489389
Entity Incorporation, State or Country Code X0
Entity Address, Address Line One 3 More London Riverside
Entity Address, City or Town London
Entity Address, Country GB
Entity Address, Postal Zip Code SE1 2RE
Country Region 44
City Area Code 203
Local Phone Number 283 4200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary shares, nominal value £0.05 per share*
Trading Symbol VRNA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Grafico Azioni Verona Pharma (NASDAQ:VRNA)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Verona Pharma
Grafico Azioni Verona Pharma (NASDAQ:VRNA)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Verona Pharma